top of page

Scientist on Tablet

News

h

EXTERNAL MEDIA COVERAGEPRESS RELEASESPUBLICATIONSTHOUGHT LEADERSHIP

THOUGHT LEADERSHIP

11 Dec 2024

Wound Care Voices: Why enzymes are just what wound care clinicians have been looking for

PRESS RELEASES

6 Nov 2024

SolasCure and U.S. Army Institute of Surgical Research collaborate for combat wound care

THOUGHT LEADERSHIP

21 Aug 2024

Wound Care Voices: Why the Battle Against Chronic Wounds is Worth Fighting

THOUGHT LEADERSHIP

4 Jul 2024

Wound Bed Preparation: Addressing the Urgent Need for Effective Solutions

PRESS RELEASES

3 Jun 2024

SolasCure Selected for Innovate UK Global Incubator Programme in Houston

PRESS RELEASES

20 Mar 2024

SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care

PRESS RELEASES

4 Mar 2024

SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal

PUBLICATIONS

22 Feb 2024

First clinical evaluation of the safety and efficacy of tarumase for the debridement of venous leg ulcers

PRESS RELEASES

12 Dec 2023

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

PRESS RELEASES

1 Nov 2023

SolasCure Awarded Prestigious European Innovation Council’s Accelerator Grant

EXTERNAL MEDIA COVERAGE

30 Oct 2023

European Innovation Council Accelerator: strong performance of engineering and tech-based companies in the latest €350 million funding round

EXTERNAL MEDIA COVERAGE

6 Jun 2023

EIT Health Catapult 2022 names SolasCure biotech winner

EXTERNAL MEDIA COVERAGE

27 Apr 2023

SolasCure raises €12M in Series B finance

PRESS RELEASES

27 Mar 2023

SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

PRESS RELEASES

16 Feb 2023

SolasCure named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade

PRESS RELEASES

17 Jan 2023

SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial

PRESS RELEASES

16 Jan 2023

SolasCure’s David Fairlamb recognised at TOPRA Awards for exceptional leadership in regulatory strategy

PUBLICATIONS

10 Jan 2023

Preliminary evidence supporting a new enzymatic debridement product for use in chronic wounds

PRESS RELEASES

27 May 2022

SolasCure wins 1st place at prestigious EIT Health Catapult biotech competition for investigational wound care product Aurase Wound Gel

PRESS RELEASES

10 May 2022

Cambridge biotech company earns international recognition as first trial patient receives treatment

THOUGHT LEADERSHIP

11 Mar 2022

Harnessing the power of maggots: Cambridge biologics company SolasCure is developing an accessible method for cleaning chronic wounds, inspired by nature’s solution

PRESS RELEASES

11 Oct 2021

Biotech start-up SolasCure has begun clinical trials of its investigational wound cleaning product, Aurase Wound Gel

THOUGHT LEADERSHIP

23 Aug 2021

Treating Chronic Wounds Effectively: The Unmet Need

EXTERNAL MEDIA COVERAGE

18 Aug 2021

Seneca Partners invests £1.2m into biotech start-up SolasCure

EXTERNAL MEDIA COVERAGE

11 Aug 2021

The Biomimicry Institute's AskNature: Improved Wound Debridement Using Maggot Enzymes

PRESS RELEASES

10 Aug 2021

SolasCure announces £15m Series A raise

EXTERNAL MEDIA COVERAGE

24 Jun 2021

6 Ireland-UK start-ups ready for the Catapult Semifinals

EXTERNAL MEDIA COVERAGE

2 Jun 2021

A Truly Revolting Treatment Is Having a Renaissance

EXTERNAL MEDIA COVERAGE

31 Aug 2019

Will chronic wounds have a better treatment? SolasCure, a new company in Hovione Capital’s portfolio.

EXTERNAL MEDIA COVERAGE

9 Sept 2018

Startup Solascure chosen for the URGO Mentorship Program

EXTERNAL MEDIA COVERAGE

22 Aug 2018

BRAIN Biotech AG announces the creation of SolasCure Ltd. to continue development of Aurase

bottom of page